A Clinical, Multicenter, Randomized, Parallel-group, Double-blind, Double-dummy, Comparative Study of Non-inferiority of the Fixed Dose Combination of Codeine 30 Mg/dipyrone 500 Mg from Eurofarma Versus Tylex® (codeine 30 Mg/paracetamol 500 Mg) in the Treatment of Moderate to Intense Pain Post-impacted Third Lower Molar Extraction

A clinical, multicenter, randomized, parallel-group, double-blind, double-dummy, comparative study of non-inferiority.
⚠️Study will only be conducted in research centers in Brazil (please do not send e-mail if your center is outside brazil).

开始日期2023-11-08

申办/合作机构

Eurofarma Laboratórios SA

CTRI/2022/07/044135

/ CompletedN/A

An open label, balanced, randomized, two-treatment, two-period, two-sequence, single oral dose, crossover, bioequivalence study of Ibuprofen sodium dihydrate 512 mg tablets of Lyrus Life Sciences Pvt. Ltd., In comparison with Nurofen Pain Relief Max Strength 512 mg Tablets (Ibuprofen sodium dihydrate 512 mg) of Reckitt Benckiser Healthcare Ltd. , in healthy, adult, human subjects under Fed conditions.

开始日期2022-07-22

申办/合作机构

Lyrus Life Sciences Pvt Ltd.初创企业

NCT05663398

/ Completed临床1期

Randomized, Two-way, Two-period, Single Oral Dose, Open-label, Crossover, Bioequivalence Study to Compare Darfen 400, 400 mg Ibuprofen Coated Tablets (512 mg Ibuprofen Sodium Dihydrate) Versus Nurofen® Forte Express, 400 mg Ibuprofen Coated Tablets (512 mg Ibuprofen Sodium Dihydrate) in Healthy Adult Male and Female Subjects Under Fasting Conditions

This study is a comparative bioavailability study performed to assess bioequivalence between Test medicinal product (Darfen 400, 400 mg ibuprofen coated tablets [512 mg ibuprofen sodium dihydrate], manufactured by PrJSC "Pharmaceutical firm "Darnitsa" [Ukraine]) and Reference medicinal product (marketed medicinal product Nurofen® Forte Express, 400 mg ibuprofen coated tablets [512 mg ibuprofen sodium dihydrate], manufactured by Reckitt Benckiser [Poland] S.A.) in healthy volunteers.

开始日期2022-05-17

申办/合作机构

Darnitsa Pharmaceutical Co.

[+1]

100 项与布洛芬钠相关的临床结果

登录后查看更多信息

100 项与布洛芬钠相关的转化医学

登录后查看更多信息

100 项与布洛芬钠相关的专利（医药）

登录后查看更多信息

25,347

项与布洛芬钠相关的文献（医药）

2025-12-31·DESIGNED MONOMERS AND POLYMERS

Fabrication and in vitro evaluation of pH/thermo dual responsive hydrogels as controlled ibuprofen sodium in situ depot

Article

作者: Metouekel, Amira ; Khan, Samiullah ; Rehman, Abdur ; Shazly, Gamal A. ; Badshah, Syed Faisal ; Dabiellil, Fakhreldeen

Ibuprofen sodium (IBP) is a commonly used NSAID for multiple pain conditions. However, despite its extensive use, it is associated with multiple GIT adverse effects after oral administration. In the present study, we have fabricated thermoresponsive gel depot using Poly (N-vinylcaprolactam) and sodium alginate as polymers. The designed formulations are intended to be used as IBP depot after being administered subcutaneously. The sol-gel phase transition temperature and gelation time of gel samples were optimized by tube inversion, rheological exploration and optical transmittances. Temperature sweep experiments confirmed that optimized gel samples have sol-gel transition between 32°C and 37°C. Swelling and in vitro drug release displayed that optimized gels have maximum swelling and IBP release at pH 7.4 and at 35°C confirming their pH/thermo sensitivity. The degradation profile of hydrogels displayed controlled degradation for 6 days that with increasing contents. MTT assay showed L929 cells displayed more than 90% cell viability against blank and IBP-loaded PNVCL/NaAlg hydrogels at optimized concentrations. Fourier transform infrared spectroscopy confirmed the polymer blend hydrogels structure formation. Thermogravimetric analysis confirmed the presence of thermoresponsive moieties and thermal stability of polymer blend hydrogel sample. While scanning electron microscopy showed that hydrogel has channels in structure that might facilitate the diffusion of solvent. Results concluded that PNVCL/NaAlg hydrogels can be utilized as IBP sustained depot following subcutaneous application invivo and GIT adverse effects could be avoided associated with its oral administration.

2025-07-01·SEPARATION AND PURIFICATION TECHNOLOGY

Enhancing electron transfer by amorphous FeOOH quantum dots during photocatalytic ozonation of ibuprofen

作者: Zhuang, Guanzheng ; Chen, Weirui ; Tian, Yingjing ; Bin, Liying ; Li, Ping ; Tang, Bing ; Yi, Yunqiang ; Fu, Siyou ; Li, Laisheng

Photocatalytic ozonation (PCO) process, as an effective water purification technol., was restrained by the low mass transfer and easy combination of photo-carriers (e^-_cb-h⁺_vb) of conventional semiconductor catalysts.To these end, this study synthesized FeOOH quantum-dots (FeOOH QDs) and boosted the PCO activity by its amorphous structure with Ibuprofen (IBP) as model pollutant. 81.5 % IBP was removed by FeOOH QDs PCO, but it was 59.1 % and 61.2 % for α-FeOOH and β-FeOOH PCO, resp.FeOOH QDs PCO performed well at alk. environment but was easily inhibited by co-existing ions like SO^2-₄, HCO^-₃, NO^-₃, and Cl^-.Compared with those of α-FeOOH and β-FeOOH, FeOOH QDs had the narrowest band gap and the lowest e^-_cb-h⁺_vb recombination, therefore, its e^-_cb was more favorable to activate O₃ into •OH.Tetrahedral Fe³⁺ and octahedral Fe³⁺ co-existed on FeOOH QDs and the tetrahedral Fe³⁺ was more conducive to the adsorption of O₃ and contributed to its better PCO activity. •OH was the major reactive oxygen species accounting for IBP degradationDuring FeOOH QDs PCO process, 3 degradation routes were proposed basing on 13 kinds byproducts.T. E. S. T. result indicated that most of the intermediates were less toxic than IBP.This study is useful for developing catalysts for PCO process.

2025-07-01·JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY A-CHEMISTRY

Albumin amplifies the dioxetane (AMPPD) chemiluminescence triggered by alkaline phosphatase: Light emerging from protein cavities

作者: Morgon, Nelson Henrique ; de Souza, Aguinaldo Robinson ; Yoguim, Mauricio Ikeda ; Ximenes, Valdecir Farias ; Barison, Leonardo Almeida

AMPPD is an abbreviation for 3-(2'-spiroadamantyl)-4-methoxy-4-(3-phosphoryloxy)-phenyl-1,2-dioxetane, a thermally stable 1,2-dioxetane derivative widely used as a chemiluminescent probe in clin. laboratories for enzyme immunoassays.AMPPD is a substrate for alk. phosphatase (ALP), the enzyme that catalyzes the remotion of the phosphoryl group of AMPPD, triggering light emission.This study investigated the impact of albumins on the AMPPD:ALP system and found that human serum albumin (HSA) increases the light emission efficiency of AMPPD:ALP by around 100 times.The efficiency of light enhancement varied depending on the type of albumin, with bovine (BSA), porcine (PSA), and rabbit (RSA) serum albumins being less effective than HSA.We conducted experiments to demonstrate that once hydrolyzed by ALP, the dephosphorylated AMPPD diffuses to site I of HSA.By studying the photophys. properties of the phenol ester generated after AMPPD cleavage, we found that its complexation with HSA caused a significant increase in its fluorescent efficiency, which explains the amplification of the chemiluminescence.Resonance energy transfer from the excited phenol ester to coumarin-153 was detected, confirming the presence of both mols. in the protein cavity.Hence, introducing fluorescent acceptors into the reaction system can adjust the emission wavelength.Besides the first direct evidence of albumin as an enhancer for chemiluminescence, the results highlight the potential interference of albumins on AMPPD-mediated assays and new biotechnol. applications.

项与布洛芬钠相关的新闻（医药）

2025-03-21

·drugs

Not Much Works To Soothe Low Back Pain, Study Says

FRIDAY, March 21, 2025 -- There are a ton of suggestions out there for soothing an aching lower back -- acupuncture, heat, cannabinoids, muscle relaxants, TENS electrical pulses, dry cupping, opioids, massage and more. But not much actually eases back pain, including those suggestions, according to a new evidence review. Only painkillers like aspirin or ibuprofen -- non-steroidal anti-inflammatory drugs (NSAIDs) -- have been shown to be moderately effective in treating short-term lower back pain based on available medical evidence, researchers concluded. There’s also some evidence that five other treatments might help long-term low back pain, researchers said -- exercise , spinal manipulation, taping, antidepressants and warming creams containing ingredients like capsaicin . Overall, only 10% of treatments for low back pain had any medical evidence supporting their potential effectiveness, and even they didn’t work that great, concluded the review in the journal BMJ Evidence-Based Medicine . “Surprisingly, we found only around one in 10 was effective and most provided pain relief that was only marginally better than placebo – in other words, our review did not find reliable evidence of large effects for any of the included treatments,” Aidan Cashin , deputy director of the Center for Pain IMPACT at Neuroscience Research Australia, said in a news release. Non-surgical treatments are considered first-line care for back pain, Cashin said. Researchers performed the evidence review to see just how well these myriad therapies work. For the review, they analyzed findings from 301 clinical trials examining 56 treatments or treatment combinations for low back pain. Results showed that no sure-fire cures for back pain are currently available. Even ones with some evidence behind them can’t be counted on to work well for everyone. “We found for acute low back pain, NSAIDs may be effective. For chronic low back pain, exercise, spinal manipulation, taping, antidepressants and TRPV1 agonists (warming creams) may be effective,” Cashin said. “However, those effects were small.” Researchers also specifically highlighted five treatments that don’t work, based on the evidence. These included three for short-term low back pain – exercise, steroid injections and acetaminophen – and two for chronic back pain, antibiotics and anesthetics. For the rest of the treatments included in the research, there was simply not enough evidence to rule one way or the other, researchers concluded. More research is needed to prove whether or not these other back pain cures might have something to them. “We need further high-quality, placebo-controlled trials to understand the efficacy of treatments and remove the uncertainty for both patients and clinical teams,” Cashin said. “Placebo-controlled studies are the gold standard for evaluating the effects of treatments, with a clear need to better understand which treatments work for people with low back pain,” he added. In the meantime, Cashin recommends that people with back pain talk to their medical team to understand the treatments available and find one that works best for them. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

临床结果

2025-03-17

·drugs

AAN: Over-the-Counter Pain Relivers Tied to Fewer Concussion Symptoms

MONDAY, March 17, 2025 -- People who take over-the-counter (OTC) pain relievers after a concussion may recover faster than those who do not, according to a study scheduled for presentation at the annual meeting of the American Academy of Neurology, to be held from April 5 to 9 in San Diego. Kyle Arnold, M.D., from the University of Washington in Seattle, and colleagues evaluated the effect of OTC analgesics on clinical outcomes after concussion. Analysis included 813 college athletes and military cadets who had concussions and took over-the-counter pain relievers ( acetaminophen , ibuprofen , or other nonsteroidal anti-inflammatory drugs) and 848 who did not take any pain relievers. The researchers found that compared to those who did not take pain relievers, people who took the pain relievers were 20 percent more likely to have a faster time before they were cleared to return to activities with no restrictions. On average, those who took the medications were cleared at 50 percent recovery two days faster, and at 90 percent recovery seven days faster versus those who took no medication. Participants who took pain relievers were 15 percent more likely to return to having no symptoms more quickly, compared to those who did not take pain relievers. Lastly, those who started using OTC pain relievers on the first day of their injury returned to play and had resolution of symptoms at 50 percent recovery eight days faster than those who started taking pain relievers after five or more days. "These preliminary results may help inform potential treatment options for people recovering from concussions, but additional studies are needed to provide more definitive recommendations," Arnold said in a statement. Press Release More Information Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

临床结果

2025-03-12

·PRNewswire

Psoriatic Arthritis Market Sees Major Shift with Growing Biosimilar Adoption | DelveInsight

The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As competition intensifies, these biosimilars are reshaping treatment choices and driving a shift in the market landscape. LAS VEGAS, March 12, 2025 /PRNewswire/ -- Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects approximately 112 per 100,000 adults worldwide. It is more prevalent in Europe and North America than in Asia and South America. In patients with psoriasis, the prevalence of psoriatic arthritis can range from 6% to 34% in Western populations. Despite its impact, many individuals with psoriatic arthritis remain undiagnosed or receive inadequate treatment, highlighting the need for increased awareness and access to specialized care. As per DelveInsight analysis, among the 7MM, the United States accounted for the highest number of prevalent cases of psoriatic arthritis in 2023, and these cases are expected to increase by the end of 2034 due to several key factors such as an increase in awareness and diagnosis, as well as the rapid prevalence of PsA. Psoriatic arthritis, occurring in approximately 20% of individuals with psoriasis, is a chronic inflammatory arthritis intricately linked to psoriatic arthritis. This aggressive condition is characterized by potential significant morbidity and compromised quality of life. Treatment approaches for psoriatic arthritis encompass a variety of strategies aimed at managing symptoms, slowing disease progression, and improving the overall quality of life. These approaches typically involve a combination of pharmacological therapies, lifestyle modifications, and, in severe cases, surgical interventions. Psoriatic arthritis treatment is highly individualized based on disease severity, response to therapy, and patient preferences, with multidisciplinary care from rheumatologists, dermatologists, and physical therapists playing a key role. Pharmacological treatment for psoriatic arthritis primarily targets inflammation and pain relief. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and naproxen, are often the first line of defense, helping to reduce pain and inflammation. Disease-modifying antirheumatic drugs (DMARDs) like methotrexate, sulfasalazine, and leflunomide are commonly prescribed to prevent joint damage and suppress the inflammatory process. For individuals with mild-to-moderate psoriatic arthritis, oral small molecules (OSMs) like OTEZLA (apremilast) offer a convenient, non-injectable option by modulating inflammatory pathways. Biologic agents have revolutionized the treatment landscape for psoriatic arthritis. These medications specifically inhibit key molecules in the inflammatory cascade. TNF inhibitors like HUMIRA (adalimumab), ENBREL (etanercept), and REMICADE (infliximab) are frontline biologics that target tumor necrosis factor, a crucial driver of inflammation. Patients who do not respond to TNF inhibitors may benefit from IL-17 inhibitors like COSENTYX (secukinumab) and TALTZ (ixekizumab) or IL-12/23 inhibitors such as STELARA (ustekinumab). Learn more about the FDA-approved psoriatic arthritis drugs @ Drugs for Psoriatic Arthritis Treatment SKYRIZI (risankizumab), developed by AbbVie, is a humanized IgG1 monoclonal antibody that acts as an interleukin-23 (IL-23) antagonist. It can be used on its own or in conjunction with non-biologic DMARDs. In June 2022, the FDA approved SKYRIZI as the first and only targeted IL-23 inhibitor for adults with active psoriatic arthritis. Another biologic, TREMFYA (guselkumab by Janssen), was approved by the FDA in July 2020 as the first monoclonal antibody that selectively binds to the p19 subunit of IL-23, further expanding treatment options for psoriatic arthritis patients. BIMZELX (bimekizumab), developed by UCB Biopharma, is a humanized monoclonal antibody that targets IL-17A and IL-17F. It received European Commission approval in June 2023 for adults with active psoriatic arthritis and axial spondyloarthritis. On September 23, 2024, the FDA approved BIMZELX for treating adults with active psoriatic arthritis, non-radiographic axial spondyloarthritis (nr-axSpA) with objective inflammation, and active ankylosing spondylitis. In Phase III studies, BIMZELX showed meaningful responses in patients with inadequate TNF inhibitor responses and those new to biologics, indicating its potential as an important treatment option for psoriatic arthritis. In cases where joint damage becomes severe and unresponsive to medical therapies, surgical interventions like joint replacement surgery may be necessary to restore function and alleviate pain. Lifestyle changes, such as regular exercise, joint protection techniques, and weight management, are also critical in managing psoriatic arthritis, as excess weight can worsen symptoms and increase disease severity. The treatment landscape for psoriatic arthritis continues to evolve, offering hope to patients with more targeted therapies and improved outcomes. As companies like UCB Biopharma, AbbVie, and Janssen advance their biologic portfolios, the future looks promising for psoriatic arthritis management. The competition in the biosimilar market is intensifying as companies introduce cost-effective alternatives to blockbuster biologics. In December 2024, Celltrion announced FDA approval for STEQEYMA (ustekinumab-stba), a biosimilar to STELARA, for subcutaneous injection or intravenous infusion in adult and pediatric patients with plaque psoriasis and psoriatic arthritis, as well as adult patients with Crohn's disease and ulcerative colitis. Simultaneously, Biocon Biologics Ltd. is strengthening its position with positive Phase III results for YESINTEK, its biosimilar to ustekinumab, in adult patients with moderate to severe chronic plaque psoriasis. The pivotal randomized, double-blind, parallel-group study demonstrated comparable efficacy and safety to the reference biologic, STELARA, and the findings are being presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida. With the approval of STEQEYMA and the promising clinical outcomes for YESINTEK, these biosimilars are poised to challenge STELARA by offering cost-effective alternatives in key immunology indications. As pricing pressures and healthcare sustainability concerns drive the demand for biosimilars, these developments mark a significant shift in the treatment landscape, providing greater accessibility and affordability for patients while increasing competition in the immunology market. To know more about psoriatic arthritis treatment options, visit @ New Treatment for Psoriatic Arthritis The psoriatic arthritis market is buzzing with numerous companies advancing treatments to cater to the growing patient base. Several therapies are expected to enter the market during the forecast period, providing new hope for patients. Some of these potential therapies include ACELYRIN Inc.'s Izokibep, Novartis Pharmaceuticals' Secukinumab, UCB Biopharma SRL's Bimekizumab, and Bristol-Myers Squibb's Deucravacitinib. Additionally, AbbVie's Upadacitinib and Risankizumab, as well as Eli Lilly and Company's Ixekizumab, are also part of the promising pipeline. Other noteworthy therapies include Sun Pharma's ILUMYA/ILUMETRI, Bristol-Myers Squibb's SOTYKTU, and Affibody's Izokibep in collaboration with Acelyrin and Inmagene. With these advancements, the psoriatic arthritis treatment landscape is set for a major shift, offering patients more tailored and effective options. The companies involved in developing biosimilars include Alvotech, Teva, Biocon Biologics, Celltrion, Fresenius Kabi, and others. Discover which therapies are expected to grab major psoriatic arthritis market share @ Psoriatic Arthritis Market Report ILUMYA/ILUMETRI by Sun Pharma is an interleukin-23 (IL-23) inhibitor classified as a humanized, anti-IL-23p19 monoclonal antibody. It works by blocking inflammatory proteins (cytokines and chemokines) in the body. By inhibiting the effects of IL-23, ILUMYA helps control the release of other inflammatory proteins, including IL-17 and TNF-α. This mechanism reduces inflammation, decreases the number of inflammatory cells in psoriatic lesions, helps prevent plaque formation, and resolves tissue damage. The drug is currently undergoing evaluation in Phase III clinical development, actively recruiting subjects with active psoriatic arthritis who have prior exposure to anti-TNF agents, as well as those who are anti-TNF naïve. SOTYKTU, developed by Bristol-Myers Squibb, is the first and only novel oral selective tyrosine kinase 2 (TYK2) inhibitor being studied across multiple immune-mediated diseases. Deucravacitinib binds to the regulatory domain of the TYK2 enzyme, inhibiting its activation. This selective inhibition reduces the release of proinflammatory cytokines and chemokines, helping to control the inflammation associated with psoriatic arthritis and alleviating its signs and symptoms. Currently, the drug is being investigated for the treatment of psoriatic arthritis in a Phase III clinical trial. Izokibep, developed by Affibody in partnership with Acelyrin and Inmagene, is a unique antibody mimetic and a novel bispecific agent that potentially targets both subunits of the IL-17A homo-dimer and serum albumin. Affibody has entered into a partnership agreement with Acelyrin for the development and commercialization of izokibep and has completed a Phase II trial. As part of this agreement, Acelyrin obtained worldwide rights to izokibep, excluding selected Asian countries, where rights have been granted to Inmagene Biopharmaceuticals. In March 2024, Acelyrin announced the release of positive top-line results from the Phase IIb/III trial, indicating that izokibep was well-tolerated with a favorable safety profile. This drug is currently in Phase III clinical trial. Discover more about drugs for psoriatic arthritis in development @ Psoriatic Arthritis Clinical Trials The anticipated launch of these emerging therapies for psoriatic arthritis is poised to transform the market landscape in the coming years. As these cutting-edge treatments continue to mature and gain regulatory approval, they are expected to reshape the psoriatic arthritis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. DelveInsight estimates that the psoriatic arthritis market size was USD 9 billion in 2021 and is expected to grow significantly in the coming years. This growth can be attributed to the introduction of upcoming therapies and the rising prevalence of the condition. The anticipated launch of these therapies is also expected to attract new entrants to the psoriatic arthritis market, resulting in increased competition and innovation. DelveInsight's latest published market report titled " Psoriatic Arthritis Market Insight, Epidemiology, and Market Forecast – 2034" will help you discover which market leader is set to capture the largest market share. The report provides comprehensive insights into country-specific treatment guidelines, patient pool analysis, and epidemiology forecasts to help understand key opportunities and assess the market's underlying potential. The psoriatic arthritis market report offers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Prevalent Cases of Psoriatic Arthritis Total Diagnosed Prevalent Cases of Psoriatic Arthritis Gender-specific Diagnosed Prevalent Cases of Psoriatic Arthritis Severity-specific Diagnosed Prevalent Cases of Psoriatic Arthritis The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM Psoriatic Arthritis market. Highlights include: 10-year Forecast 7MM Analysis Epidemiology-based Market Forecasting Historical and Forecasted Market Analysis upto 2034 Emerging Drug Market Uptake Peak Sales Analysis Key Cross Competition Analysis Industry Expert's Opinion Access and Reimbursement Download this psoriatic arthritis market report to assess the epidemiology forecasts, understand patient journeys, gain insights into KOLs' opinions about upcoming treatment paradigms, and identify the factors contributing to changes in the psoriatic arthritis market. Additionally, stay informed about the mitigating factors that can enhance your market position in the psoriatic arthritis therapeutic space. Related Reports Psoriatic Arthritis Pipeline Psoriatic Arthritis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key schizophrenia companies, including Affibody, Kymera, Selection Therapeutics GmbH, Jiangsu HengRui Medicine Co., Ltd., Nimbus Lakshmi, Inc., Hansoh BioMedical R&D Company, Bio-Thera Solutions, ACELYRIN Inc., among others. Psoriatic Arthritis Epidemiology Forecast Psoriatic Arthritis Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and Psoriatic Arthritis epidemiology trends. Ankylosing Spondylitis Market Ankylosing Spondylitis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Ankylosing Spondylitis companies, including UCB, AbbVie, Pfizer, Astella, Amgen, Janssen Biotech, Pozen, Novartis, Iroko Pharmaceuticals, Syntex Pharmaceuticals, Horizon Pharma, Eli Lilly and Company, among others. Psoriasis Market Psoriasis Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Psoriasis companies, including Amgen, Janssen, Abbvie, Novartis, AstraZeneca, Bausch Health, Eli Lilly, Sun Pharmaceutical, Janssen Biotech, UCB Inc., LEO Pharma, Promius Pharma, Mayne Pharma, Bausch Health Companies, MC2 Therapeutics, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床3期上市批准临床结果临床2期

100 项与布洛芬钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09760	布洛芬钠	M02AA13 R02AX02 M01AE01	DBSALT001483

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
关节炎疼痛	美国	Haleon US Capital LLC	2012-06-12
背痛	美国	Haleon US Capital LLC	2012-06-12
普通感冒	美国	Haleon US Capital LLC	2012-06-12
痛经	美国	Haleon US Capital LLC	2012-06-12
头痛	美国	Haleon US Capital LLC	2012-06-12
轻度疼痛	美国	Haleon US Capital LLC	2012-06-12
肌痛	美国	Haleon US Capital LLC	2012-06-12
牙痛	美国	Haleon US Capital LLC	2012-06-12
发热	澳大利亚	Reckitt Benckiser (Australia) Pty Ltd.	2008-10-28
疼痛	澳大利亚	Reckitt Benckiser (Australia) Pty Ltd.	2008-10-28

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
紧张型头痛	临床3期	美国	Pfizer Inc.	2011-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01362491 (Pubmed)	临床3期	紧张型头痛	226	Placebo	夢繭構夢鏇築觸構窪窪(鑰餘繭構糧製廠繭築鏇) = 艱鏇範獵襯衊壓觸壓築膚壓憲鏇鏇構餘膚網鏇 (獵鹹鏇餘鑰簾選積鑰膚 )	-	2015-01-01
NCT01098747 \| NCT01362491 \| NCT01216163 \| NCT01035346 \| NCT01077973 (Pubmed \| Postgrad Med)	临床3期	发作性紧张型头痛 \| 疼痛 \| 紧张型头痛 ... 更多	-	IBU(Na)	憲齋製窪淵遞觸艱鹽鹽(鹽夢淵觸艱遞膚壓築醖) = n = 1, placebo 壓網鹽鹹築顧蓋廠築鬱 (鹹積蓋築廠築餘齋願構 ) 更多	-	2015-01-01
				Standard IBU
NCT01362491 (CTgov)	临床3期	疼痛 \| 紧张型头痛	226	Ibuprofen (Ibuprofen Sodium)	選製夢衊鏇膚選醖鏇願(構選襯顧鬱製窪廠製遞) = 製築範壓鏇鏇醖壓蓋簾窪顧鹽獵窪積遞獵鬱鬱 (衊衊艱獵築齋願齋衊遞, 4.8) 更多	-	2014-07-30
				placebo+ibuprofen sodium+ibuprofen (Placebo)	選製夢衊鏇膚選醖鏇願(構選襯顧鬱製窪廠製遞) = 構膚鬱壓艱壓鏇鏇糧觸窪顧鹽獵窪積遞獵鬱鬱 (衊衊艱獵築齋願齋衊遞, 4.2) 更多